- Home
- USPH vs INBX Comparison
USPH vs INBX Comparison
Compare USPH & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | USPH | INBX |
|---|---|---|
| Founded | 1990 | 2010 |
| Country | United States | United States |
| Employees | 5500 | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | 1996 | 2024 |
Fundamental Metrics
Financial Performance| Metric | USPH | INBX |
|---|---|---|
| Price | $81.14 | $88.58 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 3 |
| Target Price | $101.67 | ★ $150.00 |
| AVG Volume (30 Days) | ★ 234.9K | 191.3K |
| Earning Date | 05-06-2026 | 05-15-2026 |
| Dividend Yield | ★ 2.57% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $780,990,000.00 | $1,300,000.00 |
| Revenue This Year | $10.62 | N/A |
| Revenue Next Year | $6.30 | N/A |
| P/E Ratio | $636.62 | ★ N/A |
| Revenue Growth | 16.33 | ★ 550.00 |
| 52 Week Low | $58.19 | $22.40 |
| 52 Week High | $93.50 | $155.29 |
Technical Indicators
Market Signals| Indicator | USPH | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 62.82 | 48.64 |
| Support Level | $80.67 | $85.94 |
| Resistance Level | $83.64 | $96.12 |
| Average True Range (ATR) | 3.41 | 5.49 |
| MACD | 0.13 | 1.53 |
| Stochastic Oscillator | 83.50 | 46.88 |
Price Performance
Historical ComparisonAbout USPH U.S. Physical Therapy Inc.
US Physical Therapy Inc through its subsidiaries operate outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. The principal payment sources for the clinics' services are managed care programs, commercial health insurance, Medicare/Medicaid, workers' compensation insurance, and proceeds from personal injury cases. Its operating segment includes Physical therapy operations and Industrial injury prevention services. The company generates maximum revenue from the Physical therapy operations segment.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.